BioNTech stock has had a tough run over the past few years and the valuation checks now lean expensive, so the current price raises questions about how much of the recovery story is already reflected in the share price.

• Over the past 5 years, BioNTech shareholders have seen the stock decline 74.4%, which puts recent short term moves into a much longer period of weak returns.
• Analyst downgrades to future revenue and earnings expectations, alongside deeper recent losses and an early outlined leadership change, can weigh on confidence in the earnings power that would be needed to support a higher valuation.
• BioNTech scores just 1 out of 6 on the broader valuation checks, which suggests the stock currently leans expensive rather than standing out as a clear bargain.

The issue now is whether BioNTech's current share price still leaves enough potential upside to compensate for the earnings and execution risks that the valuation is flagging.

Has BioNTech Run Too Far on Sales?

P/S is a useful lens for BioNTech because the business is still working through losses and reinvestment, so revenue can be a cleaner anchor than earnings.

BioNTech currently trades on a P/S multiple of 7.6x, compared with an average of 11.1x for the wider biotechs industry and a peer group average of 6.3x. On Simply Wall St’s fair P/S estimate of 5.7x, which blends the company’s growth profile, profitability record, risk and size, the current multiple sits above what would typically be expected on this framework. That gap suggests investors are already paying a premium relative to the cash flow and earnings power implied by the broader model checks.

Because analysts have recently cut their sales expectations, the P/S premium comes at a time when confidence in future revenue trends is under pressure.

On the P/S multiple, BioNTech stock appears overvalued compared with what the fair-value model suggests for this level of risk and revenue profile.

The BioNTech Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the BioNTech valuation puzzle leaves off. They spell out the specific assumptions on growth, margins and earnings that would need to hold for BioNTech's stock to be worth materially more or less than today's price, and they sit on Simply Wall St's Community page. Instead of a single valuation number, Narratives outline the future that number depends on so you can watch how closely reality tracks that path.

Community views on BioNTech are split between a pipeline driven recovery story and concern that trial and revenue risks dominate at today’s price.

Bull case: 25% undervalued

"Robust pipeline expansion in oncology, with multiple late-stage Phase II and Phase III clinical trials for BNT327 and mRNA cancer immunotherapies across high-prevalence cancers, positions BioNTech to launch multiple new products…"

Bear case: 11% overvalued

"Falling COVID-19 vaccine demand in core markets, including ongoing declines in U.S. vaccination rates and increased vaccine hesitancy globally, is expected to materially reduce long-term revenue from BioNTech's main commercial franchise…"

Do you think there's more to the story for BioNTech? Head over to our Community to see what others are saying!

The Bottom Line

BioNTech now screens as overvalued on the current P/S multiple, with the broader checks pointing to a weak overall value profile rather than a clear bargain. That does not rule out upside, but it means the stock already asks you to pay up for a recovery that still carries meaningful execution and earnings risk. The crux from here is whether BioNTech can turn its pipeline and reinvestment into reliable, non COVID driven revenue that justifies the premium multiple. If that conviction is missing, the current valuation leaves less room for error.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.